SynergyFinder™ helps to ensure that new therapies are combined in the best way possible. Many cancer therapies are applied as combination therapies. To identify the right combination of your lead compound with standards of care or new drugs, NTRC has developed SynergyFinder™.
Screening 600 to 1000 combinations within a short turnaround time: your drug candidate is tested against the full library of 160 therapeutics in selected cancer cell lines within 12 weeks. If you prefer a smaller subset, we have an exemplar library of 42 therapeutics for the mechanisms that are covered in the full library. The exemplars represent the well-known and newly investigated anti cancer drugs classes. Of course, the choice of combinatorial therapeutics and cell lines is up to you.
You may prefer to test a selection of standards of care or experimental therapeutics to combine with your drug candidate. We can assist in selecting mixtures on the basis of biomarkers and targeting, as described by Uitdehaag et al. (2015) – the choice is yours. We are happy to provide cost-free consultation if desired.
You may have a preference to first scan for synthetic lethal combinations before starting laboratory experiments with mixtures of compounds. Synthetic lethal combination partners for your compound can be identified by combining the results of cancer cell line panel proliferation assays to gene expression data, and subsequent combination with known clinically validated synthetic lethal interactions (Lee et al., 2018).
Uitdehaag et al. (2015) Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs, PLoS ONE, 10 (5): e0125021.
Lee et al. (2018) Harnessing synthetic lethality to predict the response to cancer treatment, Nature Communications, 9: 2546.